Ariniego R, Waagstein F, Mombay B, Hjalmarson A
Br Heart J. 1979 Aug;42(2):139-46. doi: 10.1136/hrt.42.2.139.
The haemodynamic effects of a new beta 1-receptor agonist, 1-(4 hydroxyphenoxy) 3-isopropylamino-2-propanol, were studied in 25 patients after acute myocardial infarction using non-invasive methods. The drug caused an increase in systolic blood pressure and pulse pressure, without change in diastolic blood pressure, and a slight increase in heart rate and reduction in the pre-ejection period. These changes were greater in patients without a history of left heart failure. It is suggested that this cardioselective drug possesses positive inotropic activity but only slight positive chronotropic activity. The substance has been further investigated as a possible antidote to unwanted cardiac side effects of the cardioselective beta-blocker, metoprolol. The changes in the cardiovascular dynamics caused by metoprolol in patients with acute myocardial infarction were promptly reversed by this new beta 1-agonist. With its positive inotropic properties and its efficacy in reversing the effects of a cardioselective beta-blocker, the drug is a potentially useful pharmacological agent to support an acutely depressed myocardium in patients on beta-blocking agents.
采用非侵入性方法,对25例急性心肌梗死后患者研究了一种新型β1受体激动剂1-(4-羟基苯氧基)-3-异丙氨基-2-丙醇的血流动力学效应。该药可使收缩压和脉压升高,舒张压无变化,心率轻度增加,射血前期缩短。在无左心衰竭病史的患者中,这些变化更为明显。提示这种心脏选择性药物具有正性肌力活性,但仅有轻微的正性变时活性。该物质已作为心脏选择性β受体阻滞剂美托洛尔不良心脏副作用的一种可能解毒剂进行了进一步研究。这种新型β1激动剂能迅速逆转美托洛尔引起的急性心肌梗死患者心血管动力学变化。鉴于其正性肌力特性以及逆转心脏选择性β受体阻滞剂作用的效能,该药对于支持使用β受体阻滞剂的患者急性抑制的心肌而言,是一种潜在有用的药理剂。